Skin Cancer Diagnostics Market Is Booming Worldwide | Latest Study Reveal for the forecast to 2028

According to our new research study on "Skin Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Type, and Screening Type," the skin cancer diagnostics market size is expected to reach US$ 5,480.45 million by 2028 from US$ 3,364.46 million in 2021; it is estimated to grow at a CAGR of 7.2% from 2021 to 2028.

Get PDF Sample Report + All Related Table and Graphs @: https://www.theinsightpartners.com/sample/TIPRE00018116/?utm_source=OpenPR&utm_medium=10129

The report highlights trends prevailing in the skin cancer diagnostics market and factors governing its growth. The increasing incidence of skin cancer and launch of new product are driving the growth of the market. However, barriers to early skin cancer diagnostics in low and middle-income countries hinders the skin cancer diagnostics market growth.

Skin Cancer Diagnostics Market: Competitive Landscape and Key Developments: SkylineDx BV; AMLo Biosciences Limited; NeraCare GmbH; DermLite LLC; bioMerieux SA; Veriskin Inc.; Castle Biosciences, Inc.; DermTech Inc.; HOFFMANN-LA ROCHE LTD., and Michelson Diagnostics Ltd are among the leading companies operating in the skin cancer diagnostics market.

Skin Cancer Diagnostics Market: Key Insights - Future Trend
The major causes non-melanoma skin cancers are exposure to higher ultraviolet radiation levels. Thus, the incidences are expected to be higher in the countries lies in decreasing latitude that have higher levels of ultraviolet radiations. According to the Skin Cancer Foundation, it is stated that over 5, 400 people globally die of non-melanoma skin cancer every month. Also, the incidences of Merkel cell carcinoma have increased by 95% between 2000-2013, however, this type is rare and aggressive form of skin cancer. Likewise, region like Europe is at higher risk of people suffering from NMSC, as in the region alone ~15 million outdoor workers are exposed to sun during their working hours without knowing the risks.

The major causes non-melanoma skin cancers are exposure to higher ultraviolet radiation levels. Thus, the incidences are expected to be higher in the countries lies in decreasing latitude that have higher levels of ultraviolet radiations. According to the Skin Cancer Foundation, it is stated that over 5, 400 people globally die of non-melanoma skin cancer every month. Also, the incidences of Merkel cell carcinoma have increased by 95% between 2000-2013, however, this type is rare and aggressive form of skin cancer. Likewise, region like Europe is at higher risk of people suffering from NMSC, as in the region alone ~15 million outdoor workers are exposed to sun during their working hours without knowing the risks.

Skin Cancer Diagnostics Market: Segmental Overview
The skin cancer diagnostics market is segmented on the basis of type, and screening type. Based on type, the market is segmented into melanoma and non-melanoma. By screening type, the skin cancer diagnostics market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests.

Have Question? Speak to Analyst @ https://www.theinsightpartners.com/speak-to-analyst/TIPRE00018116/?utm_source=OpenPR&utm_medium=10129

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.